Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of ON 01910.Na plus best supportive care versus best supportive care in higher-blast myelodysplastic syndrome after hypomethylating agent failure
2010-019755-21Phase 3Completed
- Sponsor
- Onconova Therapeutics, Inc.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myelodysplastic syndrome (MDS) comparing ON 01910.Na + best supportive care with Best supportive care (2 arms). Primary endpoint: Overall survival. Started Nov 2011; status: completed.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2010-019755-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019755-21.